Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2020 pubmed 1 citations

Diminished systemic levels of antimicrobial peptides in tuberculous lymphadenitis and their reversal after anti-tuberculosis treatment.

Kathamuthu. Gokul Raj GR; Moideen. Kadar K; Sridhar. Rathinam R; Baskaran. Dhanaraj D

Key Findings

  • TBL patients have reduced circulating granulysin and HNP1‑3 compared to latent TB and healthy controls.
  • LL‑37 levels are not significantly different in TBL patients versus controls.
  • After anti‑TB treatment, LL‑37 levels decrease while HBD‑2 and HNP1‑3 increase.
  • Granulysin and HNP1‑3 can distinguish TBL from other groups, but LL‑37 cannot.

Practical Outcomes

  • For biohackers, this study doesn’t suggest any new way to use LL‑37 for health or performance. It mainly shows that LL‑37 isn’t a useful biomarker for tuberculous lymphadenitis and that TB treatment can shift peptide levels, but there’s no actionable protocol or dosage guidance to apply.

Summary

People with tuberculous lymph node infection have lower blood levels of some antimicrobial peptides, but the level of LL‑37 (a cathelicidin peptide) stays about the same as in healthy folks. After finishing TB antibiotics, LL‑37 actually drops a bit while other peptides rise.

Abstract

Pulmonary tuberculosis is associated with higher plasma levels of antimicrobial peptides (AMPs) and lower granulysin levels. However, the association of AMPs with tuberculous lymphadenitis (TBL) is not well studied. Hence, we measured the plasma levels of human beta defensin-2 (HBD2), granulysin, human neutrophil peptides 1-3 (HNP1-3) and cathelicidin (LL37) in TBL compared to latent tuberculosis (LTB) and healthy controls (HC) and in TBL individuals upon completion of anti-tuberculosis treatment (ATT). We examined the association of AMPs with TBL lymph node culture grade or lymph node involvement. Finally, the discriminatory potential of these proteins was assessed using receiver operating characteristic (ROC) analysis. TBL individuals display significantly diminished circulating levels of AMPs (granulysin and HNP1-3) but not HBD-2 and LL-37 in comparison to LTB and HCs. Similarly, after ATT, both HBD-2 and HNP1-3 were significantly elevated and LL-37 was significantly reduced in TBL individuals. Granulysin and HNP1-3 discriminates TBL from LTB and HC individuals upon ROC analysis. AMPs did not exhibit significant correlation either with lymph node culture grades or lymph node involvement. Overall, TBL individuals show decreased AMPs and their reversal after ATT suggesting their association with underlying immune alteration in this poorly studied form of TB disease.

Study Information

Provider

pubmed

Year

2020

Date

2020-04-01T00:00:00.000Z

DOI

10.1016/j.tube.2020.101934

Citations

1

References

45